undamentalytics Newsletter
Sign in

Organon & Co. (OGN) stock

Add to watchlist

Add holding +

NYSE: OGN NYSE Pharmaceuticals Next results ~November 9, 2026

C Fundamentals grade

Organon & Co. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: after-tax interest is 54% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy.

Price vs value

Under review: after-tax interest is 54% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy. We'll show the comparison once resolved.

Organon & Co. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Value diary

Our note on each quarter Organon & files

10-Q filed October 30: Organon & Co.

Revenue for the twelve months to September 2026 was $6.10bn, down 3.2% on a year earlier, a steeper fall than the 2.5% decline a quarter earlier. Free-cash-flow margin fell to 11.1% from 12.3% a year earlier. The diluted share count is up 2.4% on a year earlier, which dilutes existing holders.

Our model value for Organon & is under review, so past values are not shown until it is resolved.

Source: 10-Q filed October 30, 2026 on SEC EDGAR · Financials · Valuation

Earlier notes (2)

10-Q filed July 31: Organon & Co.

Organon's revenue for the twelve months to June 2026 came in at $6.10bn, a decline of 3.2% against the prior year. That drop has deepened from the 2.5% fall recorded a quarter earlier, suggesting the top line is losing momentum rather than stabilising. Among the 46 pharmaceuticals companies we cover, this leaves Organon ranked 38th for growth, firmly in the bottom half of the group. Profitability has also softened: free-cash-flow margin slipped to 11.1%, down from 12.3% a year earlier. Meanwhile, the diluted share count has risen 2.4% over the same period, a dilution that works against existing holders at a time when both growth and cash conversion are moving in the wrong direction.

10-Q on SEC EDGAR

Where Organon & Co. stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $6.13bn, down 2.5% on a year earlier, about the same pace as a quarter earlier. That puts it 12 of 14 for growth among the pharmaceutical preparations companies we cover. Free-cash-flow margin fell to 9.3% from 10.5% a year earlier. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 1 of our 5 financial-health checks. At that price, our model says the market is pricing in about 4.2% a year of cash-flow growth for five years, faster than the -0.6% a year revenue growth it has delivered.

10-Q on SEC EDGAR

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Organon & Co.'s trailing-twelve-month revenue fell 3.2% year on year, with a free-cash-flow margin of 11.1%. Where it lags: long-term debt as % of assets of 63.3% ranks 48 of 53 pharmaceuticals companies we cover.

Our discounted-cash-flow model values the business at ~$37 per share in the base case (~$21–$58 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 13.1% while net income fell 57.5%: a 44pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Organon & Co.'s latest figures clears our strength thresholds.

Things to watch

  • Revenue shrinking. Revenue fell 3.2% over the last 12 months.
  • Share dilution. Diluted shares rose 2.4% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 60% and a beta of 0.8 against the S&P 500.
  • Below peers: long-term debt as % of assets. Long-term debt as % of assets of 63.3% ranks 48 of 53 pharmaceuticals companies we cover (median 23.8%).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.

Latest results: FY2026 Q3

Filed October 30, 2026
Earnings per share
$0.85 against an average estimate of $1.07: missed by 20.6%
Revenue
$1.57bn, down 1.7% on a year earlier
Next report
November 9, 2026; average EPS estimate $0.95

Organon &'s figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.1%
  • 1 week+0.6%
  • 1 month+0.7%
  • This year+93.8%
  • 1 year+106.4%
  • 5 years-54.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$6.1B
Net margin
3.5%
EPS (TTM, diluted)
$0.80

Growth

Revenue growth
−3.2%
Change in growth rate
−0.8 pts
Share count change
+2.4%

Cash

Free cash flow (TTM)
$675M
FCF margin
11.1%
Stock pay % of revenue
1.2%

Earnings

Last results
April 30, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Shareholder vote
  4. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Organon & Co. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: held for review: after-tax interest is 54% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Organon & Co. as an operating company, with every model that fits that kind of business. Cost of equity 9%: the 10-year Treasury yield (4.9%) plus a beta of 0.91 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$34 ~$34–$67 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$45 ~$38–$53 Included
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Organon & Co. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$25.21$23.98$13.16$14.47$7.13$13.82
Market value$6.4bn$6.1bn$3.4bn$3.7bn$1.9bn$3.7bn
+ Net debt (− = net cash)$8.4bn$8.2bn$8.1bn$8.2bn$8.1bn$7.1bn
Enterprise value$14.8bn$14.3bn$11.4bn$12.0bn$9.9bn$10.8bn
Multiples
Price / sales 1.0x1.0x0.5x0.6x0.3x0.6x
Price / earnings 4.7x6.7x3.3x4.3x9.9x17.3x
Price / free cash flow 3.3x9.2x6.2x4.9x3.5x5.5x
EV / EBITDA ——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

56 /100

Moderate moat

How hard Organon &'s competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 11 / 20

    Net income has been a median 7.5% of total assets over 6 years.

  • Durability 7 / 20

    Net margin has been a median 12.8%; its worst year was 3.5%.

  • Cash conversion 16 / 20

    Free cash flow was positive in 6 of 6 years, at a median 11.4% of revenue.

  • Discipline 15 / 20

    The diluted share count rose 5.1% over five years; stock-based pay has been a median 1.4% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (61 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, before the open. Analysts expect revenue of $1.6bn and EPS of $0.95 (range $0.88 to $1.05) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $3.44 −6% $6.2bn −1%
Next $3.65 +6% $6.3bn +2%

Next year's EPS estimate has moved +0.3% in 90 days, across 4 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −5.1% on 90 days ago. In the last 30 days, 0 analysts raised Organon & Co.'s forecast and 1 cut it.

Consensus EPS forecast Organon & Co., last 90 days
$3.30 $3.40 $3.50 $3.60 $3.70 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $3.62 Current fiscal year, 60 days ago: $3.43 Current fiscal year, 30 days ago: $3.43 Current fiscal year, 7 days ago: $3.36 Current fiscal year, Now: $3.44 $3.44 Next fiscal year, 90 days ago: $3.64 Next fiscal year, 60 days ago: $3.62 Next fiscal year, 30 days ago: $3.62 Next fiscal year, 7 days ago: $3.62 Next fiscal year, Now: $3.65 $3.65

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $3.62$3.64
60 days ago $3.43$3.62
30 days ago $3.43$3.62
7 days ago $3.36$3.62
Now $3.44$3.65

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $1.07 $0.85 −20.6%
Mar 2026 $0.85 $0.71 −16.8%
Dec 2025 $0.73 $0.63 −13.3%
Sept 2025 $0.93 $1.01 +8.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, April 30, 2026

No numeric guidance in Organon & Co.'s latest earnings release (filed April 30, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

4 analysts, Oct 2026
Buy00%
Hold375%
Sell125%

Monthly trend

  1. Oct 2026314
  2. Sep 2026415
  3. Aug 2026415

Counts of recommendations published by analysts covering Organon & Co., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
8.1%
of tradable shares
Days to cover
8.54
at average volume
Short interest, 1 month
+7%
to October 15, 2026
Held by institutions
85%
of shares
Held by insiders
0.5%
of shares
Employees
10,000
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +106.4%

$6.70 on October 31, 2025 to $13.82

ThenNowEffect
Revenue (last 12 months) $6.3bn $6.1bn −2.5%
Net margin 11.1% 3.4% −69.4%
P/E multiple 2.5x 17.4x +600.9%
Share count 260m 264m −1.4%

Biggest factor: p/e multiple.

Last 3 years +16.7%

$11.84 on November 3, 2023 to $13.82

ThenNowEffect
Revenue (last 12 months) $6.2bn $6.1bn −0.7%
Net margin 12.2% 3.4% −72.1%
P/E multiple 4.0x 17.4x +334.5%
Share count 256m 264m −3.1%

Biggest factor: p/e multiple.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
OGN−5%−45%+10%−51%+94%
Industry peers (median)−52%−13%−2%+9%−14%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
OGN50%50%50%42%64%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
OGN−40%−64%−36%−61%−42%
S&P 500−25%−10%−8%−19%−9%

Worst fall since May 14, 2021: 83% from March 2, 2022 to March 30, 2026. Getting back needed a 478% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$5.68 – $13.84
From 52-week high
−0.1%
vs 50-day average
+0.6%
vs 200-day average
+19.9%
Volatility (1 year)
60%
Beta vs S&P 500
0.78

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±7.9%
After a week
7 up, 5 down
typical move ±10.3%
After a month
7 up, 5 down
typical move ±11.0%
Results releasedNext dayS&P 500 next day5 days21 days
April 30, 2026 −0.4% +1.3% −0.1% +0.3%
February 12, 2026 −3.9% −1.5% +5.3% −17.4%
November 10, 2025 +10.9% +1.8% +12.8% +6.2%
August 5, 2025 −9.8% +0.3% −6.4% +0.3%
May 1, 2025 −25.8% +2.2% −30.2% −28.3%
February 13, 2025 +3.9% +1.1% +5.4% +8.2%
October 31, 2024 +0.8% −1.5% −10.1% −11.6%
August 6, 2024 −5.6% +0.2% +0.5% +7.3%
May 2, 2024 +4.1% +2.2% +8.9% +15.1%
February 15, 2024 +14.4% +0.2% +14.8% +10.5%
November 2, 2023 −9.2% +2.8% −22.0% −17.2%
August 8, 2023 +6.2% −1.1% +6.7% −9.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Organon & Co. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Organon & Co.
$6B $6.1B $6.2B $6.3B $6.4B $6.5B FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $6.3B Revenue (TTM), FY24 Q1: $6.3B Revenue (TTM), FY24 Q2: $6.3B Revenue (TTM), FY24 Q3: $6.4B Revenue (TTM), FY24 Q4: $6.4B Revenue (TTM), FY25 Q1: $6.3B Revenue (TTM), FY25 Q2: $6.3B Revenue (TTM), FY25 Q3: $6.3B Revenue (TTM), FY25 Q4: $6.2B Revenue (TTM), FY26 Q1: $6.2B Revenue (TTM), FY26 Q2: $6.1B Revenue (TTM), FY26 Q3: $6.1B $6.1B

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $6.3B
FY24 Q1 $6.3B
FY24 Q2 $6.3B
FY24 Q3 $6.4B
FY24 Q4 $6.4B
FY25 Q1 $6.3B
FY25 Q2 $6.3B
FY25 Q3 $6.3B
FY25 Q4 $6.2B
FY26 Q1 $6.2B
FY26 Q2 $6.1B
FY26 Q3 $6.1B
Revenue growth, TTM YoY Organon & Co.
-4% -2% 0% 2% 4% 6% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 1.4% Revenue growth, TTM YoY, FY24 Q1: 3.3% Revenue growth, TTM YoY, FY24 Q2: 2.9% Revenue growth, TTM YoY, FY24 Q3: 4.2% Revenue growth, TTM YoY, FY24 Q4: 2.2% Revenue growth, TTM YoY, FY25 Q1: -0.8% Revenue growth, TTM YoY, FY25 Q2: -1.0% Revenue growth, TTM YoY, FY25 Q3: -1.7% Revenue growth, TTM YoY, FY25 Q4: -2.9% Revenue growth, TTM YoY, FY26 Q1: -2.1% Revenue growth, TTM YoY, FY26 Q2: -2.5% Revenue growth, TTM YoY, FY26 Q3: -3.2% -3.2%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 1.4%
FY24 Q1 3.3%
FY24 Q2 2.9%
FY24 Q3 4.2%
FY24 Q4 2.2%
FY25 Q1 -0.8%
FY25 Q2 -1.0%
FY25 Q3 -1.7%
FY25 Q4 -2.9%
FY26 Q1 -2.1%
FY26 Q2 -2.5%
FY26 Q3 -3.2%
FCF margin (TTM) Organon & Co.
8% 10% 12% 14% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: 8.7% FCF margin (TTM), FY24 Q1: 8.0% FCF margin (TTM), FY24 Q2: 13.5% FCF margin (TTM), FY24 Q3: 11.7% FCF margin (TTM), FY24 Q4: 11.9% FCF margin (TTM), FY25 Q1: 12.3% FCF margin (TTM), FY25 Q2: 10.5% FCF margin (TTM), FY25 Q3: 12.3% FCF margin (TTM), FY25 Q4: 8.7% FCF margin (TTM), FY26 Q1: 11.1% FCF margin (TTM), FY26 Q2: 9.3% FCF margin (TTM), FY26 Q3: 11.1% 11.1%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 8.7%
FY24 Q1 8.0%
FY24 Q2 13.5%
FY24 Q3 11.7%
FY24 Q4 11.9%
FY25 Q1 12.3%
FY25 Q2 10.5%
FY25 Q3 12.3%
FY25 Q4 8.7%
FY26 Q1 11.1%
FY26 Q2 9.3%
FY26 Q3 11.1%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 7,777 6,532 6,304 6,174 6,263 6,403 6,216 6,099
Gross profit 5,503 4,413 3,922 3,880 3,748 3,715 3,313 3,240
Net income 3,218 2,160 1,351 917 1,023 864 187 213
Diluted EPS $12.69 $8.52 $5.31 $3.59 $3.99 $3.33 $0.72 $0.80
Growth (year on year)
Revenue — −16.0% −3.5% −2.1% +1.4% +2.2% −2.9% −3.2%
Net income — −32.9% −37.5% −32.1% +11.6% −15.5% −78.4% −57.5%
Diluted EPS — −32.9% −37.7% −32.4% +11.1% −16.5% −78.4% −58.5%
Margins
Gross margin 70.8% 67.6% 62.2% 62.8% 59.8% 58.0% 53.3% 53.1%
Net margin 41.4% 33.1% 21.4% 14.9% 16.3% 13.5% 3.0% 3.5%
Free-cash-flow margin 37.6% 31.1% 31.2% 10.7% 8.7% 11.9% 8.7% 11.1%
Cash flow
Cash from operations 3,020 2,284 2,160 858 799 939 700 843
Capital spending 92 255 192 196 251 175 162 168
Free cash flow 2,928 2,029 1,968 662 548 764 538 675
Stock-based pay 41 40 59 75 101 105 77 72
Free cash flow after stock pay 2,887 1,989 1,909 587 447 659 461 603
Balance sheet
Cash 0 12 737 706 693 675 574 1,455
Total debt 0 0 9,134 8,913 8,760 8,880 8,644 8,554
Net debt (negative = net cash) 0 −12 8,397 8,207 8,067 8,205 8,070 7,099
Diluted shares 254m 254m 254m 255m 256m 259m 261m 267m
Returned to shareholders
Dividends 0 0 145 290 294 297 88 20
Total returned 0 0 145 290 294 297 88 20

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 5 checks passed · September 30, 2026
What it owns · $13.4bn
Short-term assets $5.4bnLonger-term assets $8.0bn
What it owes, and who funded it · $13.4bn
Short-term liabilities $2.7bnLonger-term liabilities $9.6bnShareholders' equity $1.2bn
  • Short-term assets cover short-term liabilities $5.4bn of assets due within a year against $2.7bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $5.4bn short-term assets against $9.6bn of longer-dated liabilities.
  • More cash than debt $1.5bn of cash against $8.6bn of debt.
  • Debt below 40% of shareholders' equity Debt is 717% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt $843m of operating cash flow against $8.6bn of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Organon & Co.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Dividends (TTM)
$20M
Returned to shareholders
3%
of free cash flow
Diluted share count
+2.4%
year over year
Total shareholder yield
0.6%
dividends 0.6% + buybacks 0.0% of market value
Dividend payout ratio
9%
of net income paid out
R&D spending
5.9%
of revenue
Sales & admin spending
28.1%
of revenue
Days sales outstanding
89 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated OGN ELAN JAZZ ZTS BHC AMRX Median
Revenue, last 12 months $6.1bn $5.0bn $4.7bn $9.5bn $11.1bn $3.1bn $276m
Revenue growth, last 12 months −3.2% 12.0% 13.5% 1.5% 10.8% 9.3% 9.9%
Revenue growth, 3-year average −0.3% 5.1% 7.5% 5.0% 9.2% 10.5% 5.5%
Revenue growth, latest quarter −1.7% 10.2% 10.4% −0.2% 9.7% 9.9% 6.5%
Gross margin 53.1% 55.4% 93.0% 71.5% — 39.3% 62.0%
Operating margin — — 9.0% — 11.2% 14.6% −5.9%
Operating margin, 3-year average — — 4.5% — 14.8% 11.5% −7.4%
Net margin 3.5% −4.0% 4.4% 27.5% −7.6% 5.0% −7.3%
Cash from operations / revenue 13.8% 12.3% 35.9% 29.8% 19.9% 6.4% 10.2%
Free-cash-flow margin 11.1% 7.5% 34.4% 24.3% 16.8% 4.1% 8.6%
Free-cash-flow margin, 3-year average 11.7% 8.4% 31.6% 24.0% 13.0% 7.4% 7.4%
Stock pay / revenue 1.2% 1.4% 6.3% 1.0% 2.2% 1.1% 3.6%
Change in share count 2.4% 0.0% 3.1% −4.2% 1.9% 4.3% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth -3.2% 10.0% 57 of 74
Change in growth rate Growth -0.8pp -0.3pp 40 of 74
Gross margin Profitability 53.1% 59.8% 36 of 59
Net margin Profitability 3.5% -7.3% 30 of 75
Free-cash-flow margin Cash generation 11.1% 10.1% 34 of 74
Stock pay as % of revenue Cash generation 1.2% 3.6% 16 of 69
Long-term debt as % of assets Balance sheet 63.3% 23.8% 48 of 53
Change in share count Balance sheet 2.4% 1.5% 37 of 62
Days sales outstanding Balance sheet 89 days 72 days 39 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Nexplanon Implanon NXT $921M 14.8% ▼ 4.4%
Zetia $342M 5.5% ▲ 7.9%
Other Sundry Established Brands $338M 5.4% ▲ 3.0%
Atozet $324M 5.2% ▼ 31.5%
Other Non Opiod Pain Bone and Dermatology $301M 4.8% ▲ 2.0%
Arcoxia $265M 4.3% ▼ 1.9%
Follistim AQ $264M 4.2% ▲ 11.4%
Nasonex $262M 4.2% ▼ 5.1%
Singulair $252M 4.1% ▼ 29.8%
Renflexis $251M 4.0% ▼ 8.4%
Hadlima $228M 3.7% ▲ 60.6%
Cozaar Hyzaar $219M 3.5% ▼ 9.9%
Other Womens Health $174M 2.8% ▲ 10.1%
Emgality Ravvow $174M 2.8% ▲ 62.6%
Dulera $153M 2.5% ▼ 24.6%
Diprospan $150M 2.4% ▲ 7.9%
Fosamax $143M 2.3% ▼ 5.3%
Vtama $128M 2.1% ▲ 966.7%
Marvelon Mercilon $127M 2.0% ▼ 5.2%
Other Cardiovascular $126M 2.0% ▼ 5.3%
Clarinex $123M 2.0% ▼ 3.1%
Propecia $118M 1.9% ▲ 6.3%
Ganirelix Acetate Injection $101M 1.6% ▼ 7.3%
Vytorin $100M 1.6% ▼ 7.4%
Ontruzant $99M 1.6% ▼ 29.8%
Proscar $97M 1.6% ▲ 2.1%
Nuva Ring $91M 1.5% ▼ 20.9%
Other Sundry Products $82M 1.3% ▼ 28.7%
Brenzys $80M 1.3% ▲ 3.9%
Jada $74M 1.2% ▲ 21.3%
Other Respiratory $52M 0.8% ▼ 1.9%
Other Biosimilars $33M 0.5% ▲ 17.9%
Rosuzet $24M 0.4% ▼ 51.0%
Geography
Region Revenue Share YoY
Outside the US $4.6B 74.0% ▼ 4.5%
United States $1.6B 34.8% ▲ 2.0%
Latin America Middle East Russia and Africa $1.1B 23.2% ▲ 3.7%
Asia Pacific and Japan $1B 21.7% ▼ 4.8%
China $829M 18.0% ▼ 2.1%
Other Countries $93M 2.0% ▼ 32.1%
Europe and Canada $1.6B 26.0% ▼ 8.2%

From Organon & Co.'s 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$2.9B
Institutions reporting
618
Shares held vs prior quarter
▲ 9.5%
Positions opened / closed
108 / 91

Top buyers and sellers, Q2 2026: 226 institutions bought and 278 sold ; the biggest buyer was Pentwater Capital Management LP (+18.1M shares) and the biggest seller Vanguard Portfolio Management LLC (−6.7M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $434M 32.1M 14.8% ▲ 1.1%
Pentwater Capital Management LP $245M 18.1M 8.4% New
Vanguard Portfolio Management LLC $205M 15.1M 7.0% ▼ 30.7%
Vanguard Capital Management LLC $161M 11.9M 5.5% ▲ 1.5%
State Street Corp $131M 9.7M 4.5% ▼ 3.0%
Goldman Sachs Group Inc $70.4M 5.2M 2.4% ▲ 223.9%
UBS Group AG $65.8M 4.9M 2.2% ▲ 39.9%
Geode Capital Management, LLC $65.2M 4.8M 2.2% ▲ 1.2%
Man Group PLC $56.6M 4.2M 1.9% New
AQR Arbitrage LLC $52.4M 3.9M 1.8% New
Private Management Group Inc $50.7M 3.7M 1.7% ▼ 14.4%
LSV Asset Management $50.6M 3.7M 1.7% ▼ 48.5%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Organon & Co.'s complete shareholder register. Values are as reported by the filers ; 7 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $854,704 2 trades by 2 insiders, last 12 months Insider sales History → $553,393 2 trades by 2 insiders · 0% under pre-set plans
Net ▲ $301,311 net buying
Insider Date Trade Shares Price Value
Drinane Juliana Papa Head of Mfg & Supply August 5, 2026 Sell 14,761 $13.57 $200,307
Holzbaur Lynette SVP and Corporate Controller May 6, 2026 Buy 26,448 $13.35 $353,086
Holzbaur Lynette SVP and Corporate Controller May 6, 2026 Sell 26,448 $13.35 $353,086
Cox Carrie Smith Executive Chair November 12, 2025 Buy 65,400 $7.67 $501,618

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 2 trades and filings

In the last 12 months, 1 member of Congress disclosed 0 purchases and 2 sales of Organon & Co. shares.

  • Kevin Hern(R-OK 1):Sale (full), $1,001 - $15,000, traded August 5, 2026, filed August 12, 2026
  • Kevin Hern(R-OK 1):Sale (full), $1,001 - $15,000, traded August 5, 2026, filed August 10, 2026

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around August 4, 2026 estimated from the company's past filing pattern, not announced

  • April 30, 2026
  • February 12, 2026
  • November 10, 2025
  • August 5, 2025
  • May 1, 2025
  • February 13, 2025

Recent SEC filings

Data status

When each part of this page on Organon & Co. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Organon & Co. in brief

What does Organon & Co. do?
Organon & Co. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Organon & Co.'s stock ticker?
Organon & Co. trades under the ticker OGN on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Organon & Co.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Organon & Co. reported revenue of $6.1B, 3.2% lower than a year earlier, according to its SEC filings.
What is Organon & Co.'s free cash flow?
Organon & Co.'s free-cash-flow margin is 11.1% of revenue over the trailing twelve months, ranking 34 of the 74 pharmaceuticals companies we cover.
Who are Organon & Co.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Pentwater Capital Management LP and Vanguard Portfolio Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Organon & Co.'s market cap?
On November 2, 2026, Organon & Co.'s market capitalisation was about $3.7B, with a price-to-earnings ratio of 17.3 and net debt of $7.1B. Market figures come from third-party market data and may be delayed.
Does Organon & Co. pay a dividend?
Yes: Organon & Co. paid $20M in dividends over the trailing twelve months, a dividend yield of 0.55% and a payout ratio of 9.4%.
How much debt does Organon & Co. have?
Organon & Co.'s debt-to-equity ratio is 717.0%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Organon & Co.'s competitors?
In our Pharmaceuticals peer group, the companies closest to Organon & Co. are Elanco Animal Health Inc, Jazz Pharmaceuticals plc, Zoetis, Bausch Health Companies Inc. and Amneal Pharmaceuticals, Inc. The side-by-side comparison below sets their revenue, margins and growth against Organon & Co.'s.
Are insiders buying or selling Organon & Co. stock?
Over the last 12 months, Organon & Co.'s directors and officers reported 2 open-market purchases and 2 sales on Form 4. The insider trading page charts every trade.
When is Organon & Co.'s next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Organon & Co. announces its own schedule.